BridgeBio Pharma vs Solventum
BridgeBio Pharma (BBIO), health care, and Solventum (SOLV), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.
BridgeBio Pharma is worth $15B on the stock market and Solventum $14.6B: BridgeBio Pharma is valued at 2% more. BridgeBio Pharma's operating margin in its latest fiscal year was -104% and Solventum's 26.2%. Over the past year BridgeBio Pharma's share price has moved +17.9% and Solventum's +15.3%.
Key facts
- BridgeBio Pharma market value
- $15B
- Solventum market value
- $14.6B
- Solventum P/E
- 96.7
- BridgeBio Pharma revenue
- $502.1MFY to 2025-12-31
- Solventum revenue
- $8.3BFY to 2025-12-31
- Superinvestors holding both
- 0
Market values as of .
| Measure | BridgeBio Pharma | Solventum |
|---|---|---|
| Sector | Health Care | Health Care |
| Country | ||
| Fiscal year ends | 2025-12-31 | 2025-12-31 |
| Size | ||
| Market cap | $15Bhigher | $14.6Blower |
| Revenue | $502.1Mlower | $8.3Bhigher |
| Earnings | -$732.9Mlower | $1.6Bhigher |
| Employees | 1,081lower | 20,584higher |
| Total assets | $936Mlower | $14.3Bhigher |
| Valuation | ||
| P/E | — | 96.7 |
| P/S | 29.8higher | 1.8lower |
| P/B | — | 3.0 |
| Dividend yield | 0.00% | 0.00% |
| Profitability | ||
| Operating margin | -104%lower | 26.2%higher |
| Balance sheet | ||
| Net assets | -$2.1Blower | $5Bhigher |
| Total liabilities | $3Blower | $9.2Bhigher |
| Total debt | $2Blower | $5Bhigher |
| Cash on hand | $570.1Mlower | $878Mhigher |
| Price change | ||
| Today | -0.72%higher | -2.92%lower |
| 1 year | +17.9%higher | +15.3%lower |
Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.
Which superinvestors hold them
From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.
Both (0)
None of the tracked investors.
BridgeBio Pharma only (8)
Solventum only (6)
- Nelson Peltz15.0%
- Christopher Davis2.4%
- Diamond Hill team1.5%
- Joel Greenblatt0.1%
- Richard Pzena0.1%
- Mairs & Power team0.1%
Percentages are each holding's share of that investor's reported portfolio. Who owns BBIO · Who owns SOLV
More on BridgeBio Pharma
Further comparisons
BridgeBio Pharma against its closest peers
Solventum against its closest peers
Learn
Questions and answers
Which is bigger, BridgeBio Pharma or Solventum?
By market value, BridgeBio Pharma is the larger: $15B against $14.6B for Solventum. By revenue in its latest fiscal year, Solventum is the larger: $8.3B against $502.1M for BridgeBio Pharma.
Which has the higher operating margin?
Solventum: 26.2%, against -104% for BridgeBio Pharma. Operating margin is operating income as a share of revenue in the latest fiscal year.
Which has the higher dividend yield?
Neither: both stand at 0.00%. Dividend yield is the last twelve months' dividends as a share of today's share price.
Which has more debt?
Solventum: $5B, against $2B for BridgeBio Pharma. Total debt is borrowings at the end of the latest fiscal year, as each company reported it; it is not set against cash here.
Which superinvestors own both BridgeBio Pharma and Solventum?
None of the tracked superinvestors holds both in their latest 13F filing. 8 hold BridgeBio Pharma and 6 hold Solventum.
Cite this page
Funkfolio, “BridgeBio Pharma vs Solventum”, data as of 17 November 2026. https://funkfolio.com/compare/bbio-vs-solv
Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.